

Adopted as Rule: November 2023

Toxicological Summary for: Ethylbenzene

CAS: 100-41-4

Synonyms: Phenylethane, ethylbenzol, EB, 1-Ethylbenzene

Acute Non-Cancer Health Risk Limit (nHRL_{Acute}) = Not Derived (Insufficient Data)

Short-term Non-Cancer Health Risk Limit (nHRL_{Short-term}) = 40 µg/L

$$\frac{(\text{Reference Dose, mg/kg-d}) \times (\text{Relative Source Contribution}) \times (\text{Conversion Factor})}{(\text{Short-term Intake Rate, L/kg-d})}$$

$$= \frac{(0.06 \text{ mg/kg-d}) \times (0.2)^* \times (1000 \text{ µg/mg})}{(0.290 \text{ L/kg-d})^{**}}$$

$$= 41 \text{ rounded to } \mathbf{40 \text{ µg/L}}$$

*Relative Source Contribution: MDH 2008, Section IV.E.1.

**Intake Rate: MDH 2008, Section IV.E.1. and US EPA 2019, Exposure Factors Handbook, Tables 3-1, 3-3 and 3-5

Reference Dose/Concentration:	HED/Total UF = 18/300 = 0.06 mg/kg-d (Wistar rat)
Source of toxicity value:	Determined by MDH in 2018
Point of Departure (POD):	75 mg/kg-d (administered dose NOAEL, Mellert 2007)
Dose Adjustment Factor (DAF):	0.24, Body weight scaling, default (USEPA 2011) (MDH 2017)
Human Equivalent Dose (HED):	POD x DAF = 75 mg/kg-d x 0.24 = 18 mg/kg-d
Total uncertainty factor (UF):	300
Uncertainty factor allocation:	3 for interspecies differences (for toxicodynamics), 10 for intraspecies variability, and 10 for database uncertainty (lack of studies via oral exposure including a lack of developmental and reproductive studies and toxicity data in multiple species)
Critical effect(s):	Changes in liver and kidney weight in males with corresponding histological changes; and blood chemistry changes at higher doses
Co-critical effect(s):	None
Additivity endpoint(s):	Hepatic (liver) system, Renal (kidney) system

Subchronic Non-Cancer Health Risk Limit (nHRL_{Subchronic}) = nHRL_{Short-term} = 40 µg/L

$$\frac{(\text{Reference Dose, mg/kg-d}) \times (\text{Relative Source Contribution}) \times (\text{Conversion Factor})}{(\text{Subchronic Intake Rate, L/kg-d})}$$
$$= \frac{(0.036 \text{ mg/kg-d}) \times (0.2)^* \times (1000 \text{ µg/mg})}{(0.074 \text{ L/kg-d})^{**}}$$
$$= 97 \text{ rounded to } 100 \text{ µg/L}$$

*Relative Source Contribution: MDH 2008, Section IV.E.1.

**Intake Rate: MDH 2008, Section IV.E.1. and US EPA 2019, Exposure Factors Handbook, Tables 3-1, 3-3 and 3-5

Reference Dose/Concentration: HED/Total UF = 10.68/300 = 0.036 mg/kg-d (Wistar rat)
Source of toxicity value: ATSDR 2010
Point of Departure (POD): 6.61 µmol/L (Liver serum concentration BMDL₁₀, ATSDR 2010 analysis of Mellert 2007)
Dose Adjustment Factor (DAF): Chemical-Specific PBPK model (ATSDR 2010)
Human Equivalent Dose (HED): 10.68 mg/kg-d HED from PBPK modelling conducted by ATSDR 2010
Total uncertainty factor (UF): 300
Uncertainty factor allocation: 3 for interspecies differences (for toxicodynamics), 10 for intraspecies variability, and 10 for database uncertainty (lack of studies via oral exposure including a lack of developmental and reproductive studies and toxicity data in multiple species)
Critical effect(s): Centrilobular hepatocyte hypertrophy
Co-critical effect(s): None
Additivity endpoint(s): Hepatic (liver) system

The Subchronic nHRL must be protective of the short-term exposures that occur within the subchronic period and therefore, the Subchronic nHRL is set equal to the Short-term nHRL of 40 µg/L. Additivity endpoints: Hepatic (liver) system, Renal (kidney) system

Chronic Non-Cancer Health Risk Limit (nHRL_{Chronic}) = nHRL_{Short-term} = 40 µg/L

$$\frac{(\text{Reference Dose, mg/kg-d}) \times (\text{Relative Source Contribution}) \times (\text{Conversion Factor})}{(\text{Chronic Intake Rate, L/kg-d})}$$
$$= \frac{(0.011 \text{ mg/kg-d}) \times (0.2)^* \times (1000 \text{ µg/mg})}{(0.045 \text{ L/kg-d})^{**}}$$
$$= 48 \text{ rounded to } 50 \text{ µg/L}$$

*Relative Source Contribution: MDH 2008, Section IV.E.1.

**Intake Rate: MDH 2008, Section IV.E.1. and US EPA 2019, Exposure Factors Handbook, Tables 3-1, 3-3 and 3-5

Reference Dose/Concentration: HED/Total UF = 10.68/1000 = 0.011 mg/kg-d
(Wistar rat)
Source of toxicity value: ATSDR 2010
Point of Departure (POD): 6.61 µmol/L (BMDL₁₀ based on concentration of ethylbenzene in the liver, ATSDR 2010 analysis of Mellert 2007) (subchronic exposure)
Dose Adjustment Factor (DAF): Chemical-Specific PBPK model (ATSDR 2010)
Human Equivalent Dose (HED): 10.68 mg/kg-d HED from PBPK modelling conducted by ATSDR 2010
Total uncertainty factor (UF): 1000
Uncertainty factor allocation: 3 for interspecies differences (for toxicodynamics), 10 for intraspecies variability, 10 for database uncertainty (lack of studies via oral exposure including a lack of developmental and reproductive studies and toxicity data in multiple species), and 3 for extrapolation to a chronic duration from a subchronic duration study
Critical effect(s): Centrilobular hepatocyte hypertrophy
Co-critical effect(s): None
Additivity endpoint(s): Hepatic (liver) system

The Chronic nHRL must be protective of the short-term and subchronic exposures that occur within the chronic period and therefore, the Chronic nHRL is set equal to the Short-term nHRL of 40 µg/L. Additivity endpoints: Hepatic (liver) system, Renal (kidney) system

Cancer Health Risk Limit (cHRL) = Not Applicable

Cancer classification: 2B - possibly carcinogenic to humans (IARC 2000);
D - not classifiable as to human carcinogenicity (USEPA 1991)
Slope factor (SF): Not Applicable
Source of cancer slope factor (SF): Not Applicable
Tumor site(s): liver and kidney

Volatile: Yes (high)

Summary of Guidance Value History:

A noncancer chronic Health Risk Limit (HRL) of 700 µg/L was promulgated in 1993. In 2011, MDH derived short-term, subchronic, and chronic HRLs of 50 µg/L. In 2015, MDH evaluated the potential of incorporating an oral slope factor into the assessment. There was no new

information to support derivation of a cancer water guidance value. In 2018, MDH re-evaluated the existing HRLs, resulting in slightly lower Health Based Values (HBV). The 2018 HBVs are lower than the previous HRLs as a result of 1) use of MDH’s most recent risk assessment methodology and 2) rounding to one significant digit. In 2020 MDH incorporated updated intake rates (US EPA 2019). Use of the updated intake rates did not result in any changes to the guidance values. In November 2023, the guidance values were adopted into Minnesota Rules, 4717.7860, as Health Risk Limits (HRLs).

Summary of toxicity testing for health effects identified in the Health Standards Statute (144.0751):

Even if testing for a specific health effect was not conducted for this chemical, information about that effect might be available from studies conducted for other purposes. MDH has considered the following information in developing health protective guidance.

	Endocrine	Immunotoxicity	Development	Reproductive	Neurotoxicity
Tested for specific effect?	No	No	No	Yes	Yes
Effects observed?	_1	_2	_3	Yes ⁴	Yes ⁵

Comments on extent of testing or effects:

¹ Endocrine activity of ethylbenzene has not been tested. However, an acute oral study noted decreases in peripheral hormone levels and possible effects on the estrus cycle in rats at doses 2000 or more times higher than the short-term reference dose. Rats and mice exposed to ethylbenzene in an inhalation exposure study showed an increased incidence of follicular cell hyperplasia in the thyroid gland and hyperplasia in the pituitary gland over the two-year study period.

² Immunotoxicity of ethylbenzene has only been studied by inhalation in laboratory animals. Some studies noted changes in immune cell numbers and increased spleen weights, but these results were not consistently seen across all studies. One general toxicity oral study noted decreased thymus weights in rats exposed at doses over 900 times higher than the short-term reference dose.

³ Developmental effects have not been studied in laboratory animals exposed through the oral route. Effects observed in rat inhalation exposure studies include reduced fetal weight and skeletal and urogenital anomalies observed in the presence of maternal toxicity.

⁴ Very limited information is available on reproductive effects following oral exposures. Decreases in hormone levels affecting the estrus cycle and uterine effects were indicated in a single acute reproductive study in laboratory animals with oral exposure at doses 2000 or more times higher than the short-term reference dose. Adverse reproductive effects were not observed in laboratory animals studies with inhalation exposure.

⁵ Significant ototoxic effects have been reported, including loss of the outer hair cells in a part of the ear. This effect was observed in male rats at a single oral dose over 3000 times higher than the short-term reference dose. Ototoxicity has also been seen following inhalation exposure to ethylbenzene.

Resources Consulted During Review:

Agency for Toxic Substances and Disease Registry (ATSDR). (2010). *Toxicological Profile for Ethylbenzene*. Retrieved from <https://www.atsdr.cdc.gov/toxprofiles/tp110.pdf>.

Agency for Toxic Substances and Disease Registry (ATSDR). (2018). Minimal Risk Levels (MRLs) for Hazardous Substances. Retrieved from <https://www.atsdr.cdc.gov/mrls/mrlolist.asp>

California Water Resources Control Board. (2017). Compilation of Water Quality Goals Retrieved from https://www.waterboards.ca.gov/water_issues/programs/water_quality_goals/

Faber, W., Roberts, LSG., Stump, DG. (2006). Two-generation reproduction study of ethylbenzene by inhalation in Crt-CD rats. *Birth Defects Res B Dev Reprod Toxicol*, 77(1), 10-21.

Gangnaire, F., Langlais, C., Grossman, S. (2007). Ototoxicity in rats exposed to ethylbenzene and to two technical xylene vapours for 13 weeks. *Arch Toxicol*, 81(2), 127-143.

Government of Canada. (2016). Screening Assessment Report - Ethylbenzene Retrieved from <https://www.canada.ca/en/health-canada/services/chemical-substances/other-chemical-substances-interest/ethylbenzene.html>

Hard, G. (2002). Significance of the renal effects of ethylbenzene in rodents for assessing human carcinogenic risk. *Toxicol Sci*, 69, 30-41.

Hardin, B., Bond, GP., Sikov, MR. (1981). Testing of selected workplace chemicals for teratogenic potential. *Scand J Work Environ Health*, 7, 66-75.

Health Canada. (2014). Guidelines for Drinking Water Quality - Guideline Technical Document for Toluene, Ethylbenzene, and Xylenes. Retrieved from <https://www.canada.ca/en/health-canada/services/publications/healthy-living/guidelines-canadian-drinking-water-quality-toluene-ethylbenzene-xylenes.html?page=6&wbdisable=true>

International Agency for Research on Cancer (IARC). Complete List of Agents evaluated and their classification. Retrieved from <http://monographs.iarc.fr/ENG/Classification/index.php>

Li, A., Maurissen, JP., Barnett, JF., Foss, J., Freshwater, L., Garman, RH., Peachee, VL., Hong, SJ., Stump, DG., Bus, JS. (2010). Oral gavage subchronic neurotoxicity and inhalation subchronic immunotoxicity studies of ethylbenzene in the rat. *Neurotoxicology*, 31, 247-258.

Maltoni, C., Conti, B., Cotti, G. (1985). Experimental studies on benzene carcinogenicity at the Bologna Institute of Oncology: Current results and ongoing research. *Am J Ind Med*, 7, 415-446.

Maltoni, C., Ciliberti, A., Pinto, C. (1997). Results of long-term experimental carcinogenicity studies of the effects of gasoline, correlated fuels, and major gasoline aromatics on rats. *Ann NY Acad Sci*, 837, 15-52.

Mellert, W., Deckhardt, K., Kaufmann, W. (2007). Ethylbenzene: 4 and 13 week rat oral toxicity. *Arch Toxicol*, 81, 361-370.

Minnesota Department of Health (MDH). (2008). Statement of Need and Reasonableness (SONAR), July 11, 2008. Support document relating to Health Risk Limits for Groundwater Rules. Retrieved from <https://www.leg.state.mn.us/archive/sonar/SONAR-03733.pdf#page=2>

Minnesota Department of Health (MDH). (2017). MDH Health Risk Assessment Methods to Incorporate Human Equivalent Dose Calculations into Derivation of Oral Reference Doses (May 2011, revised 2017). Retrieved from <https://www.health.state.mn.us/communities/environment/risk/docs/guidance/hedrefguide.pdf>

National Institute for Occupational Safety and Health (NIOSH). (1981). *Teratologic assessment of ethylbenzene and 2-ethoxyethanol*. PB83208074.

National Toxicology Program (NTP). (1999). *NTP Technical report on the toxicology and carcinogenesis studies of ethylbenzene in F344/N rats and B6C3F1 mice (inhalation studies)*. NTP TR 466.

Office of Environmental Health Hazard Assessment (OEHHA). (2018). Chemicals Database Retrieved from <https://oehha.ca.gov/chemicals>

Saillenfait, A., Gallissot, F., Morel, G. (2003). Developmental toxicities of ethylbenzene, ortho-, meta-, para-xylene and technical xylenes in rats following inhalation exposure. *Food Chem Toxicol*, 41, 415-429.

Saillenfait, A., Gallissot, F., Sabate, JP. (2006). Developmental toxicity of combined ethylbenzene and methylethylketone administered by inhalation to rats. *Food Chem Toxicol*, 44(8), 1287-1298.

Ungvary, G., Tatrai, E. (1985). On the embryotoxic effects of benzene and its alkyl derivatives in mice, rats, and rabbits. *Arch Toxicol Suppl*, 8, 425-430.

United States Environmental Protection Agency (USEPA). (1988). Recommendations for and Documentation of Biological Values for Use in Risk Assessment. Office of Research and Development. Retrieved from <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=34855>

United States Environmental Protection Agency (USEPA). (1991). Integrated Risk Information System (IRIS) Chemical Assessment Summary for Ethylbenzene. Retrieved from https://cfpub.epa.gov/ncea/iris/iris_documents/documents/subst/0051_summary.pdf

United States Environmental Protection Agency (USEPA). (2008). *Child-Specific Exposure Factors Handbook*. Retrieved from <https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=199243>.

United States Environmental Protection Agency (USEPA). (2009). Provisional Peer-Reviewed Toxicity Values for Ethylbenzene. Retrieved from <https://cfpub.epa.gov/ncea/pprtv/documents/Ethylbenzene.pdf>

United States Environmental Protection Agency (USEPA). (2011). Recommended Use of Body Weight^{3/4} as the Default Method in Derivation of the Oral Reference Dose. Office of the Science Advisor. Retrieved from <https://www.epa.gov/risk/recommended-use-body-weight-34-default-method-derivation-oral-reference-dose>

United States Environmental Protection Agency (USEPA). (2014). Guidance for Applying Quantitative Data to Develop Data-Derived Extrapolation Factors for Interspecies and Intraspecies Extrapolation. Risk Assessment Forum. Office of Research and Development. EPA/100/R-14/002F.

United States Environmental Protection Agency (USEPA). (2014). *IRIS Toxicological Review of Ethylbenzene (Scoring and Problem Formulation Materials)*. (EPA/625/R-14/198).

United States Environmental Protection Agency (USEPA). (2018). 2018 Edition of the Drinking Water Standards and Health Advisories Tables.

U.S. Environmental Protection Agency (EPA). (2019). Exposure Factors Handbook Chapter 3 Update 2019. Retrieved from <https://www.epa.gov/expobox/exposure-factors-handbook-chapter-3>

Voluntary Children's Chemical Evaluation Program (VCCEP). (2010). <https://chemview.epa.gov/chemview>

Wolf, M., Rowe, VK., McCollister, DD. (1956). Toxicological studies of certain alkylated benzenes and benzene: Experiments on laboratory animals. *AMA Arch Ind Health*, 14, 387-398.

World Health Organization (WHO). (2005). Chemical-Specific Adjustment Factors for Interspecies Differences and Human Variability: Guidance Document for the Use of Data in Dose/Concentration-Response Assessment. International Programme on Chemical Safety, IPCS Harmonization Project Document No. 2. WHO/IPCS/01.4, 1-96, Geneva, Switzerland.

World Health Organization (WHO). (2008). Guidelines for Drinking-water Quality Third Edition Volume 1 Recommendations.